LEE011
| Code | Size | Price |
|---|
| SYN-1213-M100 | 100 mg | Enquire |
Quantity:
| SYN-1213-M001 | 1 mg | £69.00 |
Quantity:
| SYN-1213-M005 | 5 mg | £104.00 |
Quantity:
| SYN-1213-M010 | 10 mg | £151.00 |
Quantity:
| SYN-1213-M050 | 50 mg | £420.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
LEE-011; Ribociclib
Appearance:
Solid.
CAS:
1211441-98-3
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
InChiKey:
RHXHGRAEPCAFML-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1211441-98-3. Formula: C23H30N8O. MW: 434.5. Orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathways, with potential antineoplastic activity. Specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Molecular Formula:
C23H30N8O
Molecular Weight:
434.5
Package Type:
Plastic Vial
Product Description:
Orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathways, with potential antineoplastic activity. Specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma: J. Rader, et al.; Clin. Cancer Res. 19, 6173 (2013) | Molecular pathways: CDK4 inhibitors for cancer therapy: M.A. Dickson; Clin. Cancer Res. 20, 3379 (2014) | Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo: Y.X. Zhang, et al.; Mol. Cancer Ther. 13, 2184 (2014)
Related Products
| Product Name | Product Code | Supplier | (S)-CR8 | AG-CR1-0040 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|